PMID: 
Reviews - 5dt1 mentioned but not cited (1)
- Broadly Neutralizing Bovine Antibodies: Highly Effective New Tools against Evasive Pathogens? Burke MJ, Stockley PG, Boyes J. Viruses 12 E473 (2020)
Articles - 5dt1 mentioned but not cited (7)
- New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. Doria-Rose NA, Bhiman JN, Roark RS, Schramm CA, Gorman J, Chuang GY, Pancera M, Cale EM, Ernandes MJ, Louder MK, Asokan M, Bailer RT, Druz A, Fraschilla IR, Garrett NJ, Jarosinski M, Lynch RM, McKee K, O'Dell S, Pegu A, Schmidt SD, Staupe RP, Sutton MS, Wang K, Wibmer CK, Haynes BF, Abdool-Karim S, Shapiro L, Kwong PD, Moore PL, Morris L, Mascola JR. J Virol 90 76-91 (2016)
- Human immunoglobulin repertoire analysis guides design of vaccine priming immunogens targeting HIV V2-apex broadly neutralizing antibody precursors. Willis JR, Berndsen ZT, Ma KM, Steichen JM, Schiffner T, Landais E, Liguori A, Kalyuzhniy O, Allen JD, Baboo S, Omorodion O, Diedrich JK, Hu X, Georgeson E, Phelps N, Eskandarzadeh S, Groschel B, Kubitz M, Adachi Y, Mullin TM, Alavi NB, Falcone S, Himansu S, Carfi A, Wilson IA, Yates JR, Paulson JC, Crispin M, Ward AB, Schief WR. Immunity 55 2149-2167.e9 (2022)
- Engineering and characterising a novel, highly potent bispecific antibody iMab-CAP256 that targets HIV-1. Moshoette T, Ali SA, Papathanasopoulos MA, Killick MA. Retrovirology 16 31 (2019)
- Investigation of Sequence Clipping and Structural Heterogeneity of an HIV Broadly Neutralizing Antibody by a Comprehensive LC-MS Analysis. Ivleva VB, Schneck NA, Gollapudi D, Arnold F, Cooper JW, Lei QP. J Am Soc Mass Spectrom 29 1512-1523 (2018)
- Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half life. Zhang B, Gollapudi D, Gorman J, O'Dell S, Damron LF, McKee K, Asokan M, Yang ES, Pegu A, Lin BC, Chao CW, Chen X, Gama L, Ivleva VB, Law WH, Liu C, Louder MK, Schmidt SD, Shen CH, Shi W, Stein JA, Seaman MS, McDermott AB, Carlton K, Mascola JR, Kwong PD, Lei QP, Doria-Rose NA. Sci Rep 12 17876 (2022)
- Removal of variable domain N-linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodies. Chuang GY, Asokan M, Ivleva VB, Pegu A, Yang ES, Zhang B, Chaudhuri R, Geng H, Lin BC, Louder MK, McKee K, O'Dell S, Wang H, Zhou T, Doria-Rose NA, Kueltzo LA, Lei QP, Mascola JR, Kwong PD. MAbs 12 1836719 (2020)
- Systematic Review A potential antibody repertoire diversification mechanism through tyrosine sulfation for biotherapeutics engineering and production. Zhong X, D'Antona AM. Front Immunol 13 1072702 (2022)
Reviews citing this publication (35)
- Recent progress in broadly neutralizing antibodies to HIV. Sok D, Burton DR. Nat Immunol 19 1179-1188 (2018)
- The HIV-1 envelope glycoprotein structure: nailing down a moving target. Ward AB, Wilson IA. Immunol Rev 275 21-32 (2017)
- Native-like Env trimers as a platform for HIV-1 vaccine design. Sanders RW, Moore JP. Immunol Rev 275 161-182 (2017)
- Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development. Bonsignori M, Liao HX, Gao F, Williams WB, Alam SM, Montefiori DC, Haynes BF. Immunol Rev 275 145-160 (2017)
- Antibody responses to viral infections: a structural perspective across three different enveloped viruses. Murin CD, Wilson IA, Ward AB. Nat Microbiol 4 734-747 (2019)
- HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies. de Taeye SW, Moore JP, Sanders RW. Trends Immunol 37 221-232 (2016)
- Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention. Stephenson KE, Wagh K, Korber B, Barouch DH. Annu Rev Immunol 38 673-703 (2020)
- How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design. Pancera M, Changela A, Kwong PD. Curr Opin HIV AIDS 12 229-240 (2017)
- Broadly Neutralizing Antibodies for HIV-1 Prevention. Walsh SR, Seaman MS. Front Immunol 12 712122 (2021)
- Beyond Hot Spots: Biases in Antibody Somatic Hypermutation and Implications for Vaccine Design. Schramm CA, Douek DC. Front Immunol 9 1876 (2018)
- Engineering multi-specific antibodies against HIV-1. Padte NN, Yu J, Huang Y, Ho DD. Retrovirology 15 60 (2018)
- Neutralizing antibodies for HIV-1 prevention. Julg B, Barouch DH. Curr Opin HIV AIDS 14 318-324 (2019)
- To bnAb or Not to bnAb: Defining Broadly Neutralising Antibodies Against HIV-1. Griffith SA, McCoy LE. Front Immunol 12 708227 (2021)
- Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy? Subbaraman H, Schanz M, Trkola A. Retrovirology 15 52 (2018)
- Effective high-throughput isolation of fully human antibodies targeting infectious pathogens. Gieselmann L, Kreer C, Ercanoglu MS, Lehnen N, Zehner M, Schommers P, Potthoff J, Gruell H, Klein F. Nat Protoc 16 3639-3671 (2021)
- The Neutralizing Antibody Response to the HIV-1 Env Protein. Moore PL. Curr HIV Res 16 21-28 (2018)
- Promise and Progress of an HIV-1 Cure by Adeno-Associated Virus Vector Delivery of Anti-HIV-1 Biologics. Gardner MR. Front Cell Infect Microbiol 10 176 (2020)
- Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission? Hsu DC, Mellors JW, Vasan S. Front Immunol 12 710044 (2021)
- Strategies for inducing effective neutralizing antibody responses against HIV-1. Del Moral-Sánchez I, Sliepen K. Expert Rev Vaccines 18 1127-1143 (2019)
- A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention. Kwon YD, Asokan M, Gorman J, Zhang B, Liu Q, Louder MK, Lin BC, McKee K, Pegu A, Verardi R, Yang ES, Program VP, Carlton K, Doria-Rose NA, Lusso P, Mascola JR, Kwong PD. MAbs 13 1946918 (2021)
- Coevolution of HIV-1 and broadly neutralizing antibodies. Doria-Rose NA, Landais E. Curr Opin HIV AIDS 14 286-293 (2019)
- Tracing Antibody Repertoire Evolution by Systems Phylogeny. Yermanos AD, Dounas AK, Stadler T, Oxenius A, Reddy ST. Front Immunol 9 2149 (2018)
- Exploiting B Cell Receptor Analyses to Inform on HIV-1 Vaccination Strategies. Kreer C, Gruell H, Mora T, Walczak AM, Klein F. Vaccines (Basel) 8 E13 (2020)
- Impact of HIV-1 Diversity on Its Sensitivity to Neutralization. Stefic K, Bouvin-Pley M, Braibant M, Barin F. Vaccines (Basel) 7 E74 (2019)
- V2-Specific Antibodies in HIV-1 Vaccine Research and Natural Infection: Controllers or Surrogate Markers. Duerr R, Gorny MK. Vaccines (Basel) 7 E82 (2019)
- Targeting the N332-supersite of the HIV-1 envelope for vaccine design. Moyo T, Kitchin D, Moore PL. Expert Opin Ther Targets 24 499-509 (2020)
- An Overview of Human Anti-HIV-1 Neutralizing Antibodies against Diverse Epitopes of HIV-1. Kumar S, Singh S, Luthra K. ACS Omega 8 7252-7261 (2023)
- Algal and Cyanobacterial Lectins and Their Antimicrobial Properties. Fernández Romero JA, Paglini MG, Priano C, Koroch A, Rodríguez Y, Sailer J, Teleshova N. Mar Drugs 19 687 (2021)
- Broadly neutralizing antibodies targeting HIV: Progress and challenges. Paneerselvam N, Khan A, Lawson BR. Clin Immunol 257 109809 (2023)
- Antibody class-switching as a strategy to improve HIV-1 neutralization. Scheepers C, Richardson SI, Moyo-Gwete T, Moore PL. Trends Mol Med 28 979-988 (2022)
- Complexity of Viral Epitope Surfaces as Evasive Targets for Vaccines and Therapeutic Antibodies. Miller NL, Raman R, Clark T, Sasisekharan R. Front Immunol 13 904609 (2022)
- Immune Complex Vaccine Strategies to Combat HIV-1 and Other Infectious Diseases. Tang AF, Enyindah-Asonye G, Hioe CE. Vaccines (Basel) 9 112 (2021)
- Natural infection as a blueprint for rational HIV vaccine design. van Haaren MM, van den Kerkhof TL, van Gils MJ. Hum Vaccin Immunother 13 229-236 (2017)
- Beyond glycan barriers: non-cognate ligands and protein mimicry approaches to elicit broadly neutralizing antibodies for HIV-1. Walimbwa SI, Maly P, Kafkova LR, Raska M. J Biomed Sci 31 83 (2024)
- Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives. Mahomed S. Clin Microbiol Rev 37 e0015222 (2024)
Articles citing this publication (121)
- Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. Kong R, Xu K, Zhou T, Acharya P, Lemmin T, Liu K, Ozorowski G, Soto C, Taft JD, Bailer RT, Cale EM, Chen L, Choi CW, Chuang GY, Doria-Rose NA, Druz A, Georgiev IS, Gorman J, Huang J, Joyce MG, Louder MK, Ma X, McKee K, O'Dell S, Pancera M, Yang Y, Blanchard SC, Mothes W, Burton DR, Koff WC, Connors M, Ward AB, Kwong PD, Mascola JR. Science 352 828-833 (2016)
- Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. Song G, He WT, Callaghan S, Anzanello F, Huang D, Ricketts J, Torres JL, Beutler N, Peng L, Vargas S, Cassell J, Parren M, Yang L, Ignacio C, Smith DM, Voss JE, Nemazee D, Ward AB, Rogers T, Burton DR, Andrabi R. Nat Commun 12 2938 (2021)
- A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic β-Hairpin Structure. Lee JH, Andrabi R, Su CY, Yasmeen A, Julien JP, Kong L, Wu NC, McBride R, Sok D, Pauthner M, Cottrell CA, Nieusma T, Blattner C, Paulson JC, Klasse PJ, Wilson IA, Burton DR, Ward AB. Immunity 46 690-702 (2017)
- Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. Wagh K, Bhattacharya T, Williamson C, Robles A, Bayne M, Garrity J, Rist M, Rademeyer C, Yoon H, Lapedes A, Gao H, Greene K, Louder MK, Kong R, Karim SA, Burton DR, Barouch DH, Nussenzweig MC, Mascola JR, Morris L, Montefiori DC, Korber B, Seaman MS. PLoS Pathog 12 e1005520 (2016)
- HIV-1 Neutralizing Antibodies with Limited Hypermutation from an Infant. Simonich CA, Williams KL, Verkerke HP, Williams JA, Nduati R, Lee KK, Overbaugh J. Cell 166 77-87 (2016)
- An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus. Snijder J, Ortego MS, Weidle C, Stuart AB, Gray MD, McElrath MJ, Pancera M, Veesler D, McGuire AT. Immunity 48 799-811.e9 (2018)
- HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. Bricault CA, Yusim K, Seaman MS, Yoon H, Theiler J, Giorgi EE, Wagh K, Theiler M, Hraber P, Macke JP, Kreider EF, Learn GH, Hahn BH, Scheid JF, Kovacs JM, Shields JL, Lavine CL, Ghantous F, Rist M, Bayne MG, Neubauer GH, McMahan K, Peng H, Chéneau C, Jones JJ, Zeng J, Ochsenbauer C, Nkolola JP, Stephenson KE, Chen B, Gnanakaran S, Bonsignori M, Williams LD, Haynes BF, Doria-Rose N, Mascola JR, Montefiori DC, Barouch DH, Korber B. Cell Host Microbe 25 59-72.e8 (2019)
- Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Julg B, Tartaglia LJ, Keele BF, Wagh K, Pegu A, Sok D, Abbink P, Schmidt SD, Wang K, Chen X, Joyce MG, Georgiev IS, Choe M, Kwong PD, Doria-Rose NA, Le K, Louder MK, Bailer RT, Moore PL, Korber B, Seaman MS, Abdool Karim SS, Morris L, Koup RA, Mascola JR, Burton DR, Barouch DH. Sci Transl Med 9 eaal1321 (2017)
- Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity. Chuang GY, Geng H, Pancera M, Xu K, Cheng C, Acharya P, Chambers M, Druz A, Tsybovsky Y, Wanninger TG, Yang Y, Doria-Rose NA, Georgiev IS, Gorman J, Joyce MG, O'Dell S, Zhou T, McDermott AB, Mascola JR, Kwong PD. J Virol 91 e02268-16 (2017)
- Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. Schoofs T, Barnes CO, Suh-Toma N, Golijanin J, Schommers P, Gruell H, West AP, Bach F, Lee YE, Nogueira L, Georgiev IS, Bailer RT, Czartoski J, Mascola JR, Seaman MS, McElrath MJ, Doria-Rose NA, Klein F, Nussenzweig MC, Bjorkman PJ. Immunity 50 1513-1529.e9 (2019)
- HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage. Landais E, Murrell B, Briney B, Murrell S, Rantalainen K, Berndsen ZT, Ramos A, Wickramasinghe L, Smith ML, Eren K, de Val N, Wu M, Cappelletti A, Umotoy J, Lie Y, Wrin T, Algate P, Chan-Hui PY, Karita E, IAVI Protocol C Investigators, IAVI African HIV Research Network, Ward AB, Wilson IA, Burton DR, Smith D, Pond SLK, Poignard P. Immunity 47 990-1003.e9 (2017)
- Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease. Zhou P, Song G, Liu H, Yuan M, He WT, Beutler N, Zhu X, Tse LV, Martinez DR, Schäfer A, Anzanello F, Yong P, Peng L, Dueker K, Musharrafieh R, Callaghan S, Capozzola T, Limbo O, Parren M, Garcia E, Rawlings SA, Smith DM, Nemazee D, Jardine JG, Safonova Y, Briney B, Rogers TF, Wilson IA, Baric RS, Gralinski LE, Burton DR, Andrabi R. Immunity 56 669-686.e7 (2023)
- Multi-Donor Longitudinal Antibody Repertoire Sequencing Reveals the Existence of Public Antibody Clonotypes in HIV-1 Infection. Setliff I, McDonnell WJ, Raju N, Bombardi RG, Murji AA, Scheepers C, Ziki R, Mynhardt C, Shepherd BE, Mamchak AA, Garrett N, Karim SA, Mallal SA, Crowe JE, Morris L, Georgiev IS. Cell Host Microbe 23 845-854.e6 (2018)
- IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody. Richardson SI, Lambson BE, Crowley AR, Bashirova A, Scheepers C, Garrett N, Abdool Karim S, Mkhize NN, Carrington M, Ackerman ME, Moore PL, Morris L. PLoS Pathog 15 e1008064 (2019)
- Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. Alam SM, Aussedat B, Vohra Y, Meyerhoff RR, Cale EM, Walkowicz WE, Radakovich NA, Anasti K, Armand L, Parks R, Sutherland L, Scearce R, Joyce MG, Pancera M, Druz A, Georgiev IS, Von Holle T, Eaton A, Fox C, Reed SG, Louder M, Bailer RT, Morris L, Abdool-Karim SS, Cohen M, Liao HX, Montefiori DC, Park PK, Fernández-Tejada A, Wiehe K, Santra S, Kepler TB, Saunders KO, Sodroski J, Kwong PD, Mascola JR, Bonsignori M, Moody MA, Danishefsky S, Haynes BF. Sci Transl Med 9 eaai7521 (2017)
- Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop. Cale EM, Gorman J, Radakovich NA, Crooks ET, Osawa K, Tong T, Li J, Nagarajan R, Ozorowski G, Ambrozak DR, Asokan M, Bailer RT, Bennici AK, Chen X, Doria-Rose NA, Druz A, Feng Y, Joyce MG, Louder MK, O'Dell S, Oliver C, Pancera M, Connors M, Hope TJ, Kepler TB, Wyatt RT, Ward AB, Georgiev IS, Kwong PD, Mascola JR, Binley JM. Immunity 46 777-791.e10 (2017)
- HIV-1 vaccine design through minimizing envelope metastability. He L, Kumar S, Allen JD, Huang D, Lin X, Mann CJ, Saye-Francisco KL, Copps J, Sarkar A, Blizard GS, Ozorowski G, Sok D, Crispin M, Ward AB, Nemazee D, Burton DR, Wilson IA, Zhu J. Sci Adv 4 eaau6769 (2018)
- Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections. Wagh K, Seaman MS, Zingg M, Fitzsimons T, Barouch DH, Burton DR, Connors M, Ho DD, Mascola JR, Nussenzweig MC, Ravetch J, Gautam R, Martin MA, Montefiori DC, Korber B. PLoS Pathog 14 e1006860 (2018)
- Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. Williams WB, Meyerhoff RR, Edwards RJ, Li H, Manne K, Nicely NI, Henderson R, Zhou Y, Janowska K, Mansouri K, Gobeil S, Evangelous T, Hora B, Berry M, Abuahmad AY, Sprenz J, Deyton M, Stalls V, Kopp M, Hsu AL, Borgnia MJ, Stewart-Jones GBE, Lee MS, Bronkema N, Moody MA, Wiehe K, Bradley T, Alam SM, Parks RJ, Foulger A, Oguin T, Sempowski GD, Bonsignori M, LaBranche CC, Montefiori DC, Seaman M, Santra S, Perfect J, Francica JR, Lynn GM, Aussedat B, Walkowicz WE, Laga R, Kelsoe G, Saunders KO, Fera D, Kwong PD, Seder RA, Bartesaghi A, Shaw GM, Acharya P, Haynes BF. Cell 184 2955-2972.e25 (2021)
- Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. Julg B, Stephenson KE, Wagh K, Tan SC, Zash R, Walsh S, Ansel J, Kanjilal D, Nkolola J, Walker-Sperling VEK, Ophel J, Yanosick K, Borducchi EN, Maxfield L, Abbink P, Peter L, Yates NL, Wesley MS, Hassell T, Gelderblom HC, deCamp A, Mayer BT, Sato A, Gerber MW, Giorgi EE, Gama L, Koup RA, Mascola JR, Monczor A, Lupo S, Rolle CP, Arduino R, DeJesus E, Tomaras GD, Seaman MS, Korber B, Barouch DH. Nat Med 28 1288-1296 (2022)
- Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model. Voss JE, Andrabi R, McCoy LE, de Val N, Fuller RP, Messmer T, Su CY, Sok D, Khan SN, Garces F, Pritchard LK, Wyatt RT, Ward AB, Crispin M, Wilson IA, Burton DR. Cell Rep 21 222-235 (2017)
- Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. Roark RS, Li H, Williams WB, Chug H, Mason RD, Gorman J, Wang S, Lee FH, Rando J, Bonsignori M, Hwang KK, Saunders KO, Wiehe K, Moody MA, Hraber PT, Wagh K, Giorgi EE, Russell RM, Bibollet-Ruche F, Liu W, Connell J, Smith AG, DeVoto J, Murphy AI, Smith J, Ding W, Zhao C, Chohan N, Okumura M, Rosario C, Ding Y, Lindemuth E, Bauer AM, Bar KJ, Ambrozak D, Chao CW, Chuang GY, Geng H, Lin BC, Louder MK, Nguyen R, Zhang B, Lewis MG, Raymond DD, Doria-Rose NA, Schramm CA, Douek DC, Roederer M, Kepler TB, Kelsoe G, Mascola JR, Kwong PD, Korber BT, Harrison SC, Haynes BF, Hahn BH, Shaw GM. Science 371 eabd2638 (2021)
- SONAR: A High-Throughput Pipeline for Inferring Antibody Ontogenies from Longitudinal Sequencing of B Cell Transcripts. Schramm CA, Sheng Z, Zhang Z, Mascola JR, Kwong PD, Shapiro L. Front Immunol 7 372 (2016)
- HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes. Ditse Z, Muenchhoff M, Adland E, Jooste P, Goulder P, Moore PL, Morris L. J Virol 92 e00878-18 (2018)
- Co-evolution of HIV Envelope and Apex-Targeting Neutralizing Antibody Lineage Provides Benchmarks for Vaccine Design. Rantalainen K, Berndsen ZT, Murrell S, Cao L, Omorodion O, Torres JL, Wu M, Umotoy J, Copps J, Poignard P, Landais E, Paulson JC, Wilson IA, Ward AB. Cell Rep 23 3249-3261 (2018)
- Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses. He WT, Musharrafieh R, Song G, Dueker K, Tse LV, Martinez DR, Schäfer A, Callaghan S, Yong P, Beutler N, Torres JL, Volk RM, Zhou P, Yuan M, Liu H, Anzanello F, Capozzola T, Parren M, Garcia E, Rawlings SA, Smith DM, Wilson IA, Safonova Y, Ward AB, Rogers TF, Baric RS, Gralinski LE, Burton DR, Andrabi R. Nat Immunol 23 960-970 (2022)
- Glycans Function as Anchors for Antibodies and Help Drive HIV Broadly Neutralizing Antibody Development. Andrabi R, Su CY, Liang CH, Shivatare SS, Briney B, Voss JE, Nawazi SK, Wu CY, Wong CH, Burton DR. Immunity 47 524-537.e3 (2017)
- Effects of Darwinian Selection and Mutability on Rate of Broadly Neutralizing Antibody Evolution during HIV-1 Infection. Sheng Z, Schramm CA, Connors M, Morris L, Mascola JR, Kwong PD, Shapiro L. PLoS Comput Biol 12 e1004940 (2016)
- HIV-1 Glycan Density Drives the Persistence of the Mannose Patch within an Infected Individual. Coss KP, Vasiljevic S, Pritchard LK, Krumm SA, Glaze M, Madzorera S, Moore PL, Crispin M, Doores KJ. J Virol 90 11132-11144 (2016)
- Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants. Cunningham CK, McFarland EJ, Morrison RL, Capparelli EV, Safrit JT, Mofenson LM, Mathieson B, Valentine ME, Perlowski C, Smith B, Hazra R, Purdue L, Muresan P, Harding PA, Mbengeranwa T, Robinson LG, Wiznia A, Theron G, Lin B, Bailer RT, Mascola JR, Graham BS, IMPAACT P1112 team. J Infect Dis 222 628-636 (2020)
- Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses. Hessell AJ, Powell R, Jiang X, Luo C, Weiss S, Dussupt V, Itri V, Fox A, Shapiro MB, Pandey S, Cheever T, Fuller DH, Park B, Krebs SJ, Totrov M, Haigwood NL, Kong XP, Zolla-Pazner S. Cell Rep 28 877-895.e6 (2019)
- Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial. Mahomed S, Garrett N, Karim QA, Zuma NY, Capparelli E, Baxter C, Gengiah T, Archary D, Samsunder N, Doria-Rose N, Moore P, Williamson C, Barouch DH, Fast PE, Pozzetto B, Hankins C, Carlton K, Ledgerwood J, Morris L, Mascola J, Abdool Karim S, Abdool Karim S. BMJ Open 10 e042247 (2020)
- Automated Design by Structure-Based Stabilization and Consensus Repair to Achieve Prefusion-Closed Envelope Trimers in a Wide Variety of HIV Strains. Rawi R, Rutten L, Lai YT, Olia AS, Blokland S, Juraszek J, Shen CH, Tsybovsky Y, Verardi R, Yang Y, Zhang B, Zhou T, Chuang GY, Kwong PD, Langedijk JPM. Cell Rep 33 108432 (2020)
- Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn Infants. McFarland EJ, Cunningham CK, Muresan P, Capparelli EV, Perlowski C, Morgan P, Smith B, Hazra R, Purdue L, Harding PA, Theron G, Mujuru H, Agwu A, Purswani M, Rathore MH, Flach B, Taylor A, Lin BC, McDermott AB, Mascola JR, Graham BS, International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) P1112 Team. J Infect Dis 224 1916-1924 (2021)
- AAV-Mediated Expression of Broadly Neutralizing and Vaccine-like Antibodies Targeting the HIV-1 Envelope V2 Region. van den Berg FT, Makoah NA, Ali SA, Scott TA, Mapengo RE, Mutsvunguma LZ, Mkhize NN, Lambson BE, Kgagudi PD, Crowther C, Abdool Karim SS, Balazs AB, Weinberg MS, Ely A, Arbuthnot PB, Morris L. Mol Ther Methods Clin Dev 14 100-112 (2019)
- Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments. Hraber P, Rademeyer C, Williamson C, Seaman MS, Gottardo R, Tang H, Greene K, Gao H, LaBranche C, Mascola JR, Morris L, Montefiori DC, Korber B. J Virol 91 e00991-17 (2017)
- Development of a 3Mut-Apex-Stabilized Envelope Trimer That Expands HIV-1 Neutralization Breadth When Used To Boost Fusion Peptide-Directed Vaccine-Elicited Responses. Chuang GY, Lai YT, Boyington JC, Cheng C, Geng H, Narpala S, Rawi R, Schmidt SD, Tsybovsky Y, Verardi R, Xu K, Yang Y, Zhang B, Chambers M, Changela A, Corrigan AR, Kong R, Olia AS, Ou L, Sarfo EK, Wang S, Wu W, Doria-Rose NA, McDermott AB, Mascola JR, Kwong PD. J Virol 94 e00074-20 (2020)
- A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies. Davis-Gardner ME, Alfant B, Weber JA, Gardner MR, Farzan M. mBio 11 e03080-19 (2020)
- Analysis of B Cell Receptor Repertoires Reveals Key Signatures of the Systemic B Cell Response after SARS-CoV-2 Infection. Zhang Y, Yan Q, Luo K, He P, Hou R, Zhao X, Wang Q, Yi H, Liang H, Deng Y, Hu F, Li F, Liu X, Feng Y, Li P, Qu L, Chen Z, Pan-Hammarström Q, Feng L, Niu X, Chen L. J Virol 96 e0160021 (2022)
- Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation. Crooks ET, Grimley SL, Cully M, Osawa K, Dekkers G, Saunders K, Rämisch S, Menis S, Schief WR, Doria-Rose N, Haynes B, Murrell B, Cale EM, Pegu A, Mascola JR, Vidarsson G, Binley JM. PLoS Pathog 14 e1007024 (2018)
- Neutralizing Activity of Broadly Neutralizing anti-HIV-1 Antibodies against Primary African Isolates. Lorenzi JCC, Mendoza P, Cohen YZ, Nogueira L, Lavine C, Sapiente J, Wiatr M, Mugo NR, Mujugira A, Delany S, Lingappa J, Celum C, Seaman MS, Caskey M, Nussenzweig MC. J Virol 95 JVI.01909-20 (2021)
- Susceptibility to Neutralization by Broadly Neutralizing Antibodies Generally Correlates with Infected Cell Binding for a Panel of Clade B HIV Reactivated from Latent Reservoirs. Ren Y, Korom M, Truong R, Chan D, Huang SH, Kovacs CC, Benko E, Safrit JT, Lee J, Garbán H, Apps R, Goldstein H, Lynch RM, Jones RB. J Virol 92 e00895-18 (2018)
- V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity. van Eeden C, Wibmer CK, Scheepers C, Richardson SI, Nonyane M, Lambson B, Mkhize NN, Vijayakumar B, Sheng Z, Stanfield-Oakley S, Bhiman JN, Bekker V, Hermanus T, Mabvakure B, Ismail A, Moody MA, Wiehe K, Garrett N, Karim SA, Dirr H, Fernandes MA, Sayed Y, Shapiro L, Ferrari G, Haynes BF, Moore PL, Morris L. Cell Rep 25 3123-3135.e6 (2018)
- eCD4-Ig Limits HIV-1 Escape More Effectively than CD4-Ig or a Broadly Neutralizing Antibody. Fellinger CH, Gardner MR, Weber JA, Alfant B, Zhou AS, Farzan M. J Virol 93 e00443-19 (2019)
- Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies. Tuyishime M, Garrido C, Jha S, Moeser M, Mielke D, LaBranche C, Montefiori D, Haynes BF, Joseph S, Margolis DM, Ferrari G. J Clin Invest 130 5157-5170 (2020)
- A Bayesian phylogenetic hidden Markov model for B cell receptor sequence analysis. Dhar A, Ralph DK, Minin VN, Matsen FA. PLoS Comput Biol 16 e1008030 (2020)
- A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination. Andrews SF, Raab JE, Gorman J, Gillespie RA, Cheung CSF, Rawi R, Cominsky LY, Boyington JC, Creanga A, Shen CH, Harris DR, Olia AS, Nazzari AF, Zhou T, Houser KV, Chen GL, Mascola JR, Graham BS, Kanekiyo M, Ledgerwood JE, Kwong PD, McDermott AB. Nat Med 28 373-382 (2022)
- Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at Its Apex. Gift SK, Leaman DP, Zhang L, Kim AS, Zwick MB. J Virol 91 e01216-17 (2017)
- Immune Monitoring Reveals Fusion Peptide Priming to Imprint Cross-Clade HIV-Neutralizing Responses with a Characteristic Early B Cell Signature. Cheng C, Duan H, Xu K, Chuang GY, Corrigan AR, Geng H, O'Dell S, Ou L, Chambers M, Changela A, Chen X, Foulds KE, Sarfo EK, Jafari AJ, Hill KR, Kong R, Liu K, Todd JP, Tsybovsky Y, Verardi R, Wang S, Wang Y, Wu W, Zhou T, VRC Production Program, Arnold FJ, Doria-Rose NA, Koup RA, McDermott AB, Scorpio DG, Worobey M, Shapiro L, Mascola JR, Kwong PD. Cell Rep 32 107981 (2020)
- A non-affinity purification process for GMP production of prefusion-closed HIV-1 envelope trimers from clades A and C for clinical evaluation. Gulla K, Cibelli N, Cooper JW, Fuller HC, Schneiderman Z, Witter S, Zhang Y, Changela A, Geng H, Hatcher C, Narpala S, Tsybovsky Y, Zhang B, Vrc Production Program, McDermott AB, Kwong PD, Gowetski DB. Vaccine 39 3379-3387 (2021)
- Hidden Lineage Complexity of Glycan-Dependent HIV-1 Broadly Neutralizing Antibodies Uncovered by Digital Panning and Native-Like gp140 Trimer. He L, Lin X, de Val N, Saye-Francisco KL, Mann CJ, Augst R, Morris CD, Azadnia P, Zhou B, Sok D, Ozorowski G, Ward AB, Burton DR, Zhu J. Front Immunol 8 1025 (2017)
- HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function. Richardson SI, Ayres F, Manamela NP, Oosthuysen B, Makhado Z, Lambson BE, Morris L, Moore PL. Front Immunol 12 733958 (2021)
- Molecular Basis of Unusually High Neutralization Resistance in Tier 3 HIV-1 Strain 253-11. Moyo T, Ereño-Orbea J, Jacob RA, Pavillet CE, Kariuki SM, Tangie EN, Julien JP, Dorfman JR. J Virol 92 e02261-17 (2018)
- Neutralization Breadth and Potency of Single-Chain Variable Fragments Derived from Broadly Neutralizing Antibodies Targeting Multiple Epitopes on the HIV-1 Envelope. van Dorsten RT, Lambson BE, Wibmer CK, Weinberg MS, Moore PL, Morris L. J Virol 94 e01533-19 (2020)
- Reprogramming of the heavy-chain CDR3 regions of a human antibody repertoire. Ou T, He W, Quinlan BD, Guo Y, Tran MH, Karunadharma P, Park H, Davis-Gardner ME, Yin Y, Zhang X, Wang H, Zhong G, Farzan M. Mol Ther 30 184-197 (2022)
- Structure-based Design of Cyclically Permuted HIV-1 gp120 Trimers That Elicit Neutralizing Antibodies. Kesavardhana S, Das R, Citron M, Datta R, Ecto L, Srilatha NS, DiStefano D, Swoyer R, Joyce JG, Dutta S, LaBranche CC, Montefiori DC, Flynn JA, Varadarajan R. J Biol Chem 292 278-291 (2017)
- Phenotypic deficits in the HIV-1 envelope are associated with the maturation of a V2-directed broadly neutralizing antibody lineage. Reh L, Magnus C, Kadelka C, Kühnert D, Uhr T, Weber J, Morris L, Moore PL, Trkola A. PLoS Pathog 14 e1006825 (2018)
- Broadly neutralizing antibodies to prevent HIV-1. Cohen MS, Corey L. Science 358 46-47 (2017)
- HIV-1 Consensus Envelope-Induced Broadly Binding Antibodies. Meyerhoff RR, Scearce RM, Ogburn DF, Lockwood B, Pickeral J, Kuraoka M, Anasti K, Eudailey J, Eaton A, Cooper M, Wiehe K, Montefiori DC, Tomaras G, Ferrari G, Alam SM, Liao HX, Korber B, Gao F, Haynes BF. AIDS Res Hum Retroviruses 33 859-868 (2017)
- Identification of IOMA-class neutralizing antibodies targeting the CD4-binding site on the HIV-1 envelope glycoprotein. van Schooten J, Farokhi E, Schorcht A, van den Kerkhof TLGM, Gao H, van der Woude P, Burger JA, Meesters TGR, Bijl T, Ghalaiyini R, Turner HL, Dorning J, van Schaik BDC, van Kampen AHC, Labranche CC, Stanfield RL, Sok D, Montefiori DC, Burton DR, Seaman MS, Ozorowski G, Wilson IA, Sanders RW, Ward AB, van Gils MJ. Nat Commun 13 4515 (2022)
- Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates. Qualls ZM, Choudhary A, Honnen W, Prattipati R, Robinson JE, Pinter A. J Virol 92 e01779-17 (2018)
- Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies. Mabvakure BM, Scheepers C, Garrett N, Abdool Karim S, Williamson C, Morris L, Moore PL. J Virol 93 e01685-18 (2019)
- Sequencing HIV-neutralizing antibody exons and introns reveals detailed aspects of lineage maturation. Johnson EL, Doria-Rose NA, Gorman J, Bhiman JN, Schramm CA, Vu AQ, Law WH, Zhang B, Bekker V, Abdool Karim SS, Ippolito GC, Morris L, Moore PL, Kwong PD, Mascola JR, Georgiou G. Nat Commun 9 4136 (2018)
- Serum glycan-binding IgG antibodies in HIV-1 infection and during the development of broadly neutralizing responses. Scheepers C, Chowdhury S, Wright WS, Campbell CT, Garrett NJ, Abdool Karim Q, Abdool Karim SS, Moore PL, Gildersleeve JC, Morris L. AIDS 31 2199-2209 (2017)
- Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants. Moyo-Gwete T, Madzivhandila M, Mkhize NN, Kgagudi P, Ayres F, Lambson BE, Manamela NP, Richardson SI, Makhado Z, van der Mescht MA, de Beer Z, de Villiers TR, Burgers WA, Ntusi NAB, Rossouw T, Ueckermann V, Boswell MT, Moore PL. J Virol 96 e0055822 (2022)
- Using B cell receptor lineage structures to predict affinity. Ralph DK, Matsen FA. PLoS Comput Biol 16 e1008391 (2020)
- Chinks in the armor of the HIV-1 Envelope glycan shield: Implications for immune escape from anti-glycan broadly neutralizing antibodies. Moyo T, Ferreira RC, Davids R, Sonday Z, Moore PL, Travers SA, Wood NT, Dorfman JR. Virology 501 12-24 (2017)
- HIV-1 neutralizing antibodies elicited in humans by a prefusion-stabilized envelope trimer form a reproducible class targeting fusion peptide. Wang S, Matassoli F, Zhang B, Liu T, Shen CH, Bylund T, Johnston T, Henry AR, Teng IT, Tripathi P, Becker JE, Changela A, Chaudhary R, Cheng C, Gaudinski M, Gorman J, Harris DR, Lee M, Morano NC, Novik L, O'Dell S, Olia AS, Parchment DK, Rawi R, Roberts-Torres J, Stephens T, Tsybovsky Y, Wang D, Van Wazer DJ, Zhou T, Doria-Rose NA, Koup RA, Shapiro L, Douek DC, McDermott AB, Kwong PD. Cell Rep 42 112755 (2023)
- Key Positions of HIV-1 Env and Signatures of Vaccine Efficacy Show Gradual Reduction of Population Founder Effects at the Clade and Regional Levels. Han C, Johnson J, Dong R, Kandula R, Kort A, Wong M, Yang T, Breheny PJ, Brown GD, Haim H. mBio 11 e00126-20 (2020)
- Mechanistic principles of an ultra-long bovine CDR reveal strategies for antibody design. Svilenov HL, Sacherl J, Protzer U, Zacharias M, Buchner J. Nat Commun 12 6737 (2021)
- Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes. Tanaka K, Kuwata T, Alam M, Kaplan G, Takahama S, Valdez KPR, Roitburd-Berman A, Gershoni JM, Matsushita S. Retrovirology 14 44 (2017)
- A diverse collection of B cells responded to HIV infection in infant BG505. Simonich C, Shipley MM, Doepker L, Gobillot T, Garrett M, Cale EM, Hennessy B, Itell H, Chohan V, Doria-Rose N, Nduati R, Overbaugh J. Cell Rep Med 2 100314 (2021)
- Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency. Zhang B, Gorman J, Kwon YD, Pegu A, Chao CW, Liu T, Asokan M, Bender MF, Bylund T, Damron L, Gollapudi D, Lei P, Li Y, Liu C, Louder MK, McKee K, Olia AS, Rawi R, Schön A, Wang S, Yang ES, Yang Y, Carlton K, Doria-Rose NA, Shapiro L, Seaman MS, Mascola JR, Kwong PD. MAbs 15 2165390 (2023)
- Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody. Heydarchi B, Fong DS, Gao H, Salazar-Quiroz NA, Edwards JM, Gonelli CA, Grimley S, Aktepe TE, Mackenzie C, Wales WJ, van Gils MJ, Cupo A, Rouiller I, Gooley PR, Moore JP, Sanders RW, Montefiori D, Sethi A, Purcell DFJ. Cell Rep Med 3 100635 (2022)
- Conditional antibody expression to avoid central B cell deletion in humanized HIV-1 vaccine mouse models. Tian M, McGovern K, Cheng HL, Waddicor P, Rieble L, Dao M, Chen Y, Kimble MT, Cantor E, Manfredonia N, Judson R, Chapdelaine-Williams A, Cain DW, Haynes BF, Alt FW. Proc Natl Acad Sci U S A 117 7929-7940 (2020)
- Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines. Weiss S, Itri V, Pan R, Jiang X, Luo CC, Morris L, Malherbe DC, Barnette P, Alexander J, Kong XP, Haigwood NL, Hessell AJ, Duerr R, Zolla-Pazner S. Nat Commun 13 903 (2022)
- In vitro affinity maturation of broader and more-potent variants of the HIV-1-neutralizing antibody CAP256-VRC26.25. Yin Y, Quinlan BD, Ou T, Guo Y, He W, Farzan M. Proc Natl Acad Sci U S A 118 e2106203118 (2021)
- Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials. Mkhize NN, Yssel AEJ, Kaldine H, van Dorsten RT, Woodward Davis AS, Beaume N, Matten D, Lambson B, Modise T, Kgagudi P, York T, Westfall DH, Giorgi EE, Korber B, Anthony C, Mapengo RE, Bekker V, Domin E, Eaton A, Deng W, DeCamp A, Huang Y, Gilbert PB, Gwashu-Nyangiwe A, Thebus R, Ndabambi N, Mielke D, Mgodi N, Karuna S, Edupuganti S, Seaman MS, Corey L, Cohen MS, Hural J, McElrath MJ, Mullins JI, Montefiori D, Moore PL, Williamson C, Morris L. PLoS Pathog 19 e1011469 (2023)
- Tyrosine O-sulfation proteoforms affect HIV-1 monoclonal antibody potency. Cai CX, Doria-Rose NA, Schneck NA, Ivleva VB, Tippett B, Shadrick WR, O'Connell S, Cooper JW, Schneiderman Z, Zhang B, Gowetski DB, Blackstock D, Demirji J, Lin BC, Gorman J, Liu T, Li Y, McDermott AB, Kwong PD, Carlton K, Gall JG, Lei QP. Sci Rep 12 8433 (2022)
- Analysis of 5518 unique, productively rearranged human VH3-23*01 gene sequences reveals CDR-H3 length-dependent usage of the IGHD2 gene family. Chen L, Duan Y, Benatuil L, Stine WB. Protein Eng Des Sel 30 603-609 (2017)
- Antigenic analysis of the HIV-1 envelope trimer implies small differences between structural states 1 and 2. Cale EM, Driscoll JI, Lee M, Gorman J, Zhou T, Lu M, Geng H, Lai YT, Chuang GY, Doria-Rose NA, Mothes W, Kwong PD, Mascola JR. J Biol Chem 298 101819 (2022)
- Immune inactivation of anti-simian immunodeficiency virus chimeric antigen receptor T cells in rhesus macaques. Haeseleer F, Fukazawa Y, Park H, Varco-Merth B, Rust BJ, Smedley JV, Eichholz K, Peterson CW, Mason R, Kiem HP, Roederer M, Picker LJ, Okoye AA, Corey L. Mol Ther Methods Clin Dev 22 304-319 (2021)
- An HIV Vaccine Targeting the V2 Region of the HIV Envelope Induces a Highly Durable Polyfunctional Fc-Mediated Antibody Response in Rhesus Macaques. Powell RL, Weiss S, Fox A, Liu X, Itri V, Jiang X, Luo CC, Spencer DA, Pandey S, Cheever T, Fuller DH, Totrov M, Hessell AJ, Haigwood NL, Kong XP, Zolla-Pazner S. J Virol 94 e01175-20 (2020)
- Combinations of Single Chain Variable Fragments From HIV Broadly Neutralizing Antibodies Demonstrate High Potency and Breadth. van Dorsten RT, Wagh K, Moore PL, Morris L. Front Immunol 12 734110 (2021)
- Development of Neutralization Breadth against Diverse HIV-1 by Increasing Ab-Ag Interface on V2. Gao N, Gai Y, Meng L, Wang C, Wang W, Li X, Gu T, Louder MK, Doria-Rose NA, Wiehe K, Nazzari AF, Olia AS, Gorman J, Rawi R, Wu W, Smith C, Khant H, de Val N, Yu B, Luo J, Niu H, Tsybovsky Y, Liao H, Kepler TB, Kwong PD, Mascola JR, Qin C, Zhou T, Yu X, Gao F. Adv Sci (Weinh) 9 e2200063 (2022)
- Functional development of a V3/glycan-specific broadly neutralizing antibody isolated from a case of HIV superinfection. Shipley MM, Mangala Prasad V, Doepker LE, Dingens A, Ralph DK, Harkins E, Dhar A, Arenz D, Chohan V, Weight H, Mandaliya K, Bloom JD, Matsen FA, Lee KK, Overbaugh JM. Elife 10 e68110 (2021)
- HIV-1 bispecific antibody iMab-N6 exhibits enhanced breadth but not potency over its parental antibodies iMab and N6. Moshoette T, Papathanasopoulos MA, Killick MA. Virol J 19 143 (2022)
- Hydrolysis-Kinetic Study of AEBSF, a Protease Inhibitor Used during Cell-Culture Processing of the HIV-1 Broadly Neutralizing Antibody CAP256-VRC25.26. Huang JL, Nagy A, Ivleva VB, Blackstock D, Arnold F, Cai CX. Anal Chem 90 4293-4296 (2018)
- Somatic hypermutation to counter a globally rare viral immunotype drove off-track antibodies in the CAP256-VRC26 HIV-1 V2-directed bNAb lineage. Sacks D, Bhiman JN, Wiehe K, Gorman J, Kwong PD, Morris L, Moore PL. PLoS Pathog 15 e1008005 (2019)
- Structure of an influenza group 2-neutralizing antibody targeting the hemagglutinin stem supersite. Cheung CS, Gorman J, Andrews SF, Rawi R, Reveiz M, Shen CH, Wang Y, Harris DR, Nazzari AF, Olia AS, Raab J, Teng IT, Verardi R, Wang S, Yang Y, Chuang GY, McDermott AB, Zhou T, Kwong PD. Structure 30 993-1003.e6 (2022)
- Antibody Recognition of CD4-Induced Open HIV-1 Env Trimers. Yang Z, Dam KA, Gershoni JM, Zolla-Pazner S, Bjorkman PJ. J Virol 96 e0108222 (2022)
- Characterization of AEBSF-antibody modifications for a protease inhibitor supplementation strategy. Cai CX, Schneck NA, Zhao W, Blackstock D, Cai J, Harris D, Ivleva VB, Gollapudi D, Horwitz J, Arnold FJ, Cooper JW, Lei QP. Anal Bioanal Chem 411 6111-6118 (2019)
- Double and Triple Combinations of Broadly Neutralizing Antibodies Provide Efficient Neutralization of All HIV-1 Strains from the Global Panel. Kochina EA, Urusov FA, Kruglov AA, Glazkova DV, Shipulin GA, Bogoslovskaya EV. Viruses 14 1910 (2022)
- HIV-1 infections with multiple founders associate with the development of neutralization breadth. Lewitus E, Townsley SM, Li Y, Donofrio GC, Dearlove BL, Bai H, Sanders-Buell E, O'Sullivan AM, Bose M, Kibuuka H, Maganga L, Nitayaphan S, Sawe FK, Eller LA, Michael NL, Polonis VR, Ake JA, Vasan S, Robb ML, Tovanabutra S, Krebs SJ, Rolland M. PLoS Pathog 18 e1010369 (2022)
- Heavy-chain CDR3-engineered B cells facilitate in vivo evaluation of HIV-1 vaccine candidates. He W, Ou T, Skamangas N, Bailey CC, Bronkema N, Guo Y, Yin Y, Kobzarenko V, Zhang X, Pan A, Liu X, Xu J, Zhang L, Allwardt AE, Mitra D, Quinlan B, Sanders RW, Choe H, Farzan M. Immunity 56 2408-2424.e6 (2023)
- Soluble prefusion-closed HIV-envelope trimers with glycan-covered bases. Olia AS, Cheng C, Zhou T, Biju A, Harris DR, Changela A, Duan H, Ivleva VB, Kong WP, Ou L, Rawi R, Tsybovsky Y, Van Wazer DJ, Corrigan AR, Gonelli CA, Lee M, McKee K, Narpala S, O'Dell S, Parchment DK, Stancofski ED, Stephens T, Tan I, Teng IT, Wang S, Wei Q, Yang Y, Yang Z, Zhang B, VRC Production Program, Novak J, Renfrow MB, Doria-Rose NA, Koup RA, McDermott AB, Gall JG, Lei QP, Mascola JR, Kwong PD. iScience 26 107403 (2023)
- A Perspective on Nanotechnology and COVID-19 Vaccine Research and Production in South Africa. Dube A, Egieyeh S, Balogun M. Viruses 13 2095 (2021)
- Envelope characteristics in individuals who developed neutralizing antibodies targeting different epitopes in HIV-1 subtype C infection. Ndlovu B, Gounder K, Muema D, Raju N, Hermanus T, Mthethwa Q, Robertson K, Walker BD, Georgiev IS, Morris L, Moore PL, Ndung'u T. Virology 546 1-12 (2020)
- HIV Immunology Goes Out On a Limb. Doria-Rose NA, Mascola JR. Immunity 44 1088-1090 (2016)
- Neutralization diversity of HIV-1 Indian subtype C envelopes obtained from cross sectional and followed up individuals against broadly neutralizing monoclonal antibodies having distinct gp120 specificities. Mullick R, Sutar J, Hingankar N, Deshpande S, Thakar M, Sahay S, Ringe RP, Mukhopadhyay S, Patil A, Bichare S, Murugavel KG, Srikrishnan AK, Goyal R, Sok D, Bhattacharya J. Retrovirology 18 12 (2021)
- Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidase. Lederhofer J, Tsybovsky Y, Nguyen L, Raab JE, Creanga A, Stephens T, Gillespie RA, Syeda HZ, Fisher BE, Skertic M, Yap C, Schaub AJ, Rawi R, Kwong PD, Graham BS, McDermott AB, Andrews SF, King NP, Kanekiyo M. Immunity 57 574-586.e7 (2024)
- Recognition determinants of improved HIV-1 neutralization by a heavy chain matured pediatric antibody. Kumar S, Singh S, Chatterjee A, Bajpai P, Sharma S, Katpara S, Lodha R, Dutta S, Luthra K. iScience 26 107579 (2023)
- Anti-PD-1 chimeric antigen receptor T cells efficiently target SIV-infected CD4+ T cells in germinal centers. Eichholz K, Fukazawa Y, Peterson CW, Haeseleer F, Medina M, Hoffmeister S, Duell DM, Varco-Merth BD, Dross S, Park H, Labriola CS, Axthelm MK, Murnane RD, Smedley JV, Jin L, Gong J, Rust BJ, Fuller DH, Kiem HP, Picker LJ, Okoye AA, Corey L. J Clin Invest 134 e169309 (2024)
- Complementary Roles of Antibody Heavy and Light Chain Somatic Hypermutation in Conferring Breadth and Potency to the HIV-1-Specific CAP256-VRC26 bNAb Lineage. Sacks D, Wiehe K, Morris L, Moore PL. J Virol 96 e0027022 (2022)
- Dependence on a variable residue limits the breadth of an HIV MPER neutralizing antibody, despite convergent evolution with broadly neutralizing antibodies. Scheepers C, Kgagudi P, Mzindle N, Gray ES, Moyo-Gwete T, Lambson BE, Oosthuysen B, Mabvakure B, Garrett NJ, Abdool Karim SS, Morris L, Moore PL. PLoS Pathog 18 e1010450 (2022)
- Optimal sequence-based design for multi-antigen HIV-1 vaccines using minimally distant antigens. Lewitus E, Hoang J, Li Y, Bai H, Rolland M. PLoS Comput Biol 18 e1010624 (2022)
- Reconstruction of a polyclonal ADCC antibody repertoire from an HIV-1 non-transmitting mother. Yaffe ZA, Ding S, Sung K, Chohan V, Marchitto L, Doepker L, Ralph D, Nduati R, Matsen FA, Finzi A, Overbaugh J. iScience 26 106762 (2023)
- Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines. Del Moral-Sánchez I, Wee EG, Xian Y, Lee WH, Allen JD, Torrents de la Peña A, Fróes Rocha R, Ferguson J, León AN, Koekkoek S, Schermer EE, Burger JA, Kumar S, Zwolsman R, Brinkkemper M, Aartse A, Eggink D, Han J, Yuan M, Crispin M, Ozorowski G, Ward AB, Wilson IA, Hanke T, Sliepen K, Sanders RW. NPJ Vaccines 9 74 (2024)
- Ultrapotent Broadly Neutralizing Human-llama Bispecific Antibodies against HIV-1. Xu J, Zhou T, McKee K, Zhang B, Liu C, Nazzari AF, Pegu A, Shen CH, Becker JE, Bender MF, Chan P, Changela A, Chaudhary R, Chen X, Einav T, Kwon YD, Lin BC, Louder MK, Merriam JS, Morano NC, O'Dell S, Olia AS, Rawi R, Roark RS, Stephens T, Teng IT, Tourtellott-Fogt E, Wang S, Yang ES, Shapiro L, Tsybovsky Y, Doria-Rose NA, Casellas R, Kwong PD. Adv Sci (Weinh) 11 e2309268 (2024)
- A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope. Joshi VR, Claiborne DT, Pack ML, Power KA, Newman RM, Batorsky R, Bean DJ, Goroff MS, Lingwood D, Seaman MS, Rosenberg E, Allen TM. J Virol 98 e0172023 (2024)
- Absolute quantitation of binding antibodies from clinical samples. Tang C, Verwilligen A, Sadoff J, Brandenburg B, Sneekes-Vriese E, van den Kerkhof T, Dillen L, Rutten L, Juraszek J, Callewaert K, Janssen S, Huizingh J, Euler Z, Schilperoord T, Verhemeldonck M, Langedijk JPM, Hendriks J, Stieh DJ. NPJ Vaccines 9 8 (2024)
- Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAPRISA 012C trial. Mahomed S, Garrett N, Potloane D, Sikazwe IT, Capparelli E, Harkoo I, Gengiah TN, Zuma NY, Osman F, Mansoor L, Archary D, Myeni N, Radebe P, Samsunder N, Doria-Rose N, Carlton K, Gama L, Koup RA, Narpala S, Serebryannyy L, Moore P, Williamson C, Pozzetto B, Hankins C, Morris L, Karim QA, Abdool Karim S. BMJ Open 13 e076843 (2023)
- Immunization of cows with HIV envelope trimers generates broadly neutralizing antibodies to the V2-apex from the ultralong CDRH3 repertoire. Altman PX, Ozorowski G, Stanfield RL, Haakenson J, Appel M, Parren M, Lee WH, Sang H, Woehl J, Saye-Francisco K, Sewall LM, Joyce C, Song G, Porter K, Landais E, Andrabi R, Wilson IA, Ward AB, Mwangi W, Smider VV, Burton DR, Sok D. PLoS Pathog 20 e1012042 (2024)
- In vivo affinity maturation of mouse B cells reprogrammed to express human antibodies. Yin Y, Guo Y, Jiang Y, Quinlan B, Peng H, Crynen G, He W, Zhang L, Ou T, Bailey CC, Farzan M. Nat Biomed Eng 8 361-379 (2024)
- Long trimer-immunization interval and appropriate adjuvant reduce immune responses to the soluble HIV-1-envelope trimer base. Duan H, Corrigan AR, Cheng C, Biju A, Gonelli CA, Olia AS, Teng IT, Xu K, O'Dell S, Narpala S, Castro M, Serebryannyy L, Wang J, Parchment DK, Sarfo EK, van Schooten J, Todd JP, Wang S, Harris DR, Geng H, Jafari AJ, VRC Production Program, Woodward RA, Doria-Rose NA, Foulds KE, McDermott AB, van Gils MJ, Koup RA, Pierson TC, Kwong PD, Mascola JR. iScience 27 108877 (2024)
- Predicting Antibody Neutralization Efficacy in Hypermutated Epitopes Using Monte Carlo Simulations. Amengual-Rigo P, Carrillo J, Blanco J, Guallar V. Polymers (Basel) 12 E2392 (2020)
- Preventing breast milk HIV transmission using broadly neutralizing monoclonal antibodies: One size does not fit all. Van de Perre P, Scarlatti G, Moore PL, Molès JP, Nagot N, Tylleskär T, Gray G, Goga A. Immun Inflamm Dis 12 e1216 (2024)
- Recapitulation of HIV-1 Neutralization Breadth in Plasma by the Combination of Two Broadly Neutralizing Antibodies from Different Lineages in the Same SHIV-Infected Rhesus Macaque. Gai Y, Gao N, Mou Z, Yang C, Wang L, Ji W, Gu T, Yu B, Wang C, Yu X, Gao F. Int J Mol Sci 25 7200 (2024)
- Safety and pharmacokinetics of subcutaneous administration of broadly neutralizing anti-HIV-1 monoclonal antibodies (bNAbs), given to HIV-1 exposed, uninfected neonates and infants: study protocol for a phase I trial. Goga A, Ramraj T, Naidoo L, Daniels B, Matlou M, Chetty T, Dassaye R, Ngandu NK, Galli L, Reddy T, Seocharan I, Ndlangamandla Q, September Q, Ngcobo N, Reddy M, Cafun-Naidoo T, Woeber K, Jeenarain N, Imamdin R, Maharajh K, Ramjeth A, Bhengu T, Clarence E, Van de Perre P, Tylleskär T, Nagot N, Moles JP, Moore PL, Mkhize NN, Gama L, Dispinseri S, Biswas P, Scarlatti G, PedMAb1 clinical trial team. BMC Infect Dis 24 712 (2024)
- Transient proteolysis reduction of Nicotiana benthamiana-produced CAP256 broadly neutralizing antibodies using CRISPR/Cas9. Singh AA, Pillay P, Naicker P, Alexandre K, Malatji K, Mach L, Steinkellner H, Vorster J, Chikwamba R, Tsekoa TL. Front Plant Sci 13 953654 (2022)
- Tyrosine Sulfation at Antibody Light Chain CDR-1 Increases Binding Affinity and Neutralization Potency to Interleukine-4. D'Antona AM, Lee JM, Zhang M, Friedman C, He T, Mosyak L, Bennett E, Lin L, Silverman M, Cometa F, Meade C, Hageman T, Sousa E, Cohen J, Marquette K, Ferguson D, Zhong X. Int J Mol Sci 25 1931 (2024)